Gunjan L Shah1, Navneet Majhail2, Nandita Khera3, Sergio Giralt4. 1. Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 298, New York, NY, 10065, USA. shahg@mskcc.org. 2. Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, OH, USA. 3. Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA. 4. Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 298, New York, NY, 10065, USA.
Abstract
PURPOSE OF REVIEW: Improved tolerability and outcomes after hematopoietic cell transplantation (HCT), along with the availability of alternative donors, have expanded its use. With this growth, and the development of additional cellular therapies, we also aim to increase effectiveness, efficiency, and the quality of the care provided. Fundamentally, the goal of value-based care is to have better health outcomes with streamlined processes, improved patient experience, and lower costs for both the patients and the health care system. HCT and cellular therapy treatments are multiphase treatments which allow for interventions at each juncture. RECENT FINDINGS: We present a summary of the current literature with focus on program structure and overall system capacity, coordination of therapy across providers, standardization across institutions, diversity and disparities in care, patient quality of life, and cost implications. Each of these topics provides challenges and opportunities to improve value-based care for HCT and cellular therapy patients.
PURPOSE OF REVIEW: Improved tolerability and outcomes after hematopoietic cell transplantation (HCT), along with the availability of alternative donors, have expanded its use. With this growth, and the development of additional cellular therapies, we also aim to increase effectiveness, efficiency, and the quality of the care provided. Fundamentally, the goal of value-based care is to have better health outcomes with streamlined processes, improved patient experience, and lower costs for both the patients and the health care system. HCT and cellular therapy treatments are multiphase treatments which allow for interventions at each juncture. RECENT FINDINGS: We present a summary of the current literature with focus on program structure and overall system capacity, coordination of therapy across providers, standardization across institutions, diversity and disparities in care, patient quality of life, and cost implications. Each of these topics provides challenges and opportunities to improve value-based care for HCT and cellular therapy patients.
Entities:
Keywords:
CAR-T cell; Cellular therapy; Hematopoietic cell transplantation; Value-base care
Authors: Kitsada Wudhikarn; Martina Pennisi; Marta Garcia-Recio; Jessica R Flynn; Aishat Afuye; Mari Lynne Silverberg; Molly A Maloy; Sean M Devlin; Connie Lee Batlevi; Gunjan L Shah; Michael Scordo; Maria Lia Palomba; Parastoo B Dahi; Craig S Sauter; Bianca D Santomasso; Elena Mead; Miguel-Angel Perales Journal: Blood Adv Date: 2020-07-14